圣湘生物(688289) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,378,295,460.19, representing an increase of 11.25% year-over-year[9]. - The net profit attributable to shareholders for Q3 2022 was ¥473,436,697.42, a decrease of 25.59% compared to the same period last year[9]. - The basic earnings per share for Q3 2022 were ¥0.81, down 24.68% year-over-year[12]. - The weighted average return on equity for Q3 2022 was 6.34%, a decrease of 4.19 percentage points compared to the same period last year[12]. - The company's net profit for the third quarter of 2022 was approximately ¥1.60 billion, a decrease from ¥1.76 billion in the same period of 2021, representing a decline of about 9.06%[35]. - Operating profit for the third quarter of 2022 was approximately ¥1.89 billion, down from ¥2.07 billion in the previous year, indicating a decrease of around 8.54%[35]. - The total comprehensive income for the third quarter of 2022 was approximately ¥1.61 billion, compared to ¥1.77 billion in the same period of 2021, indicating a decline of about 9.3%[38]. - The company reported a tax expense of approximately ¥272.82 million for the third quarter of 2022, a decrease from ¥300.19 million in the same period of 2021[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥8,597,332,591.32, reflecting a year-over-year increase of 21.25%[12]. - The company's total assets as of September 30, 2022, amounted to ¥8,597,332,591.32, compared to ¥7,090,370,148.22 at the end of 2021, reflecting a growth of 21.2%[31]. - The total liabilities increased to ¥864,770,293.63 from ¥709,029,210.22, marking a rise of 22%[29]. - The company reported a total equity attributable to shareholders of ¥7,720,799,786.18, which is a 21.23% increase from the end of the previous year[12]. - The company's equity attributable to shareholders increased to ¥7,720,799,786.18 from ¥6,368,907,121.24, reflecting a growth of 21.3%[32]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥1,227,927,781.28, down 14.24% year-over-year[12]. - Cash flow from operating activities for the first nine months of 2022 was approximately ¥1.23 billion, a decrease of about 14.2% from ¥1.43 billion in the same period of 2021[40]. - The company reported cash inflow from investment activities of approximately ¥7.43 billion for the first nine months of 2022, significantly higher than ¥3.99 billion in the same period of 2021[43]. - The net cash flow from investment activities for the first nine months of 2022 was approximately -¥1.08 billion, an improvement from -¥1.43 billion in the same period of 2021[43]. - Cash and cash equivalents decreased to ¥2,457,151,066.75 from ¥2,636,222,732.29, a decline of 6.8%[23]. - The cash and cash equivalents at the end of the third quarter of 2022 were approximately ¥2.45 billion, an increase from ¥2.35 billion at the end of the same period in 2021[43]. Research and Development - Research and development expenses for Q3 2022 amounted to ¥79,035,747.52, up 103.59% year-over-year, indicating a strong focus on innovation[12]. - The proportion of R&D expenses to operating revenue was 5.73%, an increase of 2.60 percentage points compared to the same period last year[12]. - Research and development expenses increased to ¥180,146,814.37, a rise of 97.5% compared to ¥91,242,557.34 in the previous year[32]. Revenue and Costs - Total operating revenue for the first three quarters of 2022 reached ¥4,068,233,187.27, an increase of 24.5% compared to ¥3,267,195,316.27 in the same period of 2021[32]. - Total operating costs for the same period were ¥2,237,583,317.43, up 74.7% from ¥1,281,834,656.42 in 2021[32]. - Total revenue from operating activities for the first nine months of 2022 reached approximately ¥4.34 billion, an increase of about 31.3% compared to ¥3.31 billion in the same period of 2021[40]. Inventory and Receivables - Inventory levels rose significantly to ¥555,999,970.98, compared to ¥369,503,323.71, an increase of 50.5%[27]. - The company reported a significant increase in accounts receivable, which rose to ¥938,517,850.95 from ¥794,673,471.33, an increase of 18.1%[23].